<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">9105085</PMID><DateCompleted><Year>1997</Year><Month>05</Month><Day>07</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1073-449X</ISSN><JournalIssue CitedMedium="Print"><Volume>155</Volume><Issue>4</Issue><PubDate><Year>1997</Year><Month>Apr</Month></PubDate></JournalIssue><Title>American journal of respiratory and critical care medicine</Title><ISOAbbreviation>Am J Respir Crit Care Med</ISOAbbreviation></Journal><ArticleTitle>Eosinophil chemotaxis inhibited by 5-lipoxygenase blockade and leukotriene receptor antagonism.</ArticleTitle><Pagination><MedlinePgn>1398-403</MedlinePgn></Pagination><Abstract><AbstractText>We studied the effects of the 5-lipoxygenase inhibition and sulfidopeptidyl leukotriene receptor antagonism on lumenal chemotaxis of eosinophils in 124 guinea pig tracheal explant preparations from 62 animals. Cell migration was assessed histologically and by differential cell count, and airway narrowing was measured by calibrated micrometry. Intralumenal instillation of the chemotaxin, formyl-met-leu-phe (FMLP) caused migration of 163,509 +/- 18,103 eosinophils/cm segment (eos/cm) versus 15,443 +/- 3,557 eos/cm for segments receiving vehicle only (p &lt; 0.001). Coincubation of FMLP with zileuton, a selective inhibitor of 5-lipoxygenase, caused a concentration-related inhibition of eosinophil migration. At 10(-10) M zileuton, cell migration caused by FMLP was decreased by 57% and nearly complete reduction to 17,200 +/- 3,620 eos/cm resulted after 10(-6) M zileuton (p &lt; 0.001 versus FMLP). Lumenal narrowing caused by FMLP (15.3 +/- 3.4%) was attenuated maximally to 1.15 +/- 2.51% after 10(-8) M zileuton (p &lt; 0.02). In 36 preparations, concentration of leukotriene B4 (LTB4) was measured in treated tracheal perfusate. LTB4 secretion caused by FMLP was 6.4 +/- 0.48 pg/ml versus 3.32 +/- 0.89 pg/ml for buffer control at 5 min (p &lt; 0.02) and was undetectable 120 min after activation with FMLP. Blockade of LTB4-receptor with the selective antagonist, LTB4 dimethyl amide, caused &gt; 90% inhibition of eosinophil migration (p &lt; 0.001). Comparable results were obtained with zafirlukast, an LTD4-receptor antagonist. Our data demonstrate that both LTB4 and LTD4 facilitate eosinophil migration from lamina propria to lumen caused by the chemotaxin, FMLP, and that LTB4-induced eosinophil migration is accompanied by initial lumenal secretion of LTB4.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mu√±oz</LastName><ForeName>N M</ForeName><Initials>NM</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Chicago, Illinois 60637, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Douglas</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Mayer</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Herrnreiter</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>X</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Leff</LastName><ForeName>A R</ForeName><Initials>AR</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AI-34566</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL-46368</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL-56399</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Respir Crit Care Med</MedlineTA><NlmUniqueID>9421642</NlmUniqueID><ISSNLinking>1073-449X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007211">Indoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020024">Leukotriene Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016859">Lipoxygenase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048448">Phenylcarbamates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018077">Receptors, Leukotriene</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018102">Receptors, Leukotriene B4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014105">Tosyl Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>1HGW4DR56D</RegistryNumber><NameOfSubstance UI="D007975">Leukotriene B4</NameOfSubstance></Chemical><Chemical><RegistryNumber>59880-97-6</RegistryNumber><NameOfSubstance UI="D009240">N-Formylmethionine Leucyl-Phenylalanine</NameOfSubstance></Chemical><Chemical><RegistryNumber>73836-78-9</RegistryNumber><NameOfSubstance UI="D017998">Leukotriene D4</NameOfSubstance></Chemical><Chemical><RegistryNumber>AJT72OTM42</RegistryNumber><NameOfSubstance UI="C412375">cysteinyl leukotriene receptor 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>LRF7RW46ID</RegistryNumber><NameOfSubstance UI="C083169">leukotriene D4 receptor</NameOfSubstance></Chemical><Chemical><RegistryNumber>V1L22WVE2S</RegistryNumber><NameOfSubstance UI="C063449">zileuton</NameOfSubstance></Chemical><Chemical><RegistryNumber>X6Q56QN5QC</RegistryNumber><NameOfSubstance UI="D006918">Hydroxyurea</NameOfSubstance></Chemical><Chemical><RegistryNumber>XZ629S5L50</RegistryNumber><NameOfSubstance UI="C062735">zafirlukast</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002634" MajorTopicYN="N">Chemotaxis, Leukocyte</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004804" MajorTopicYN="N">Eosinophils</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006168" MajorTopicYN="N">Guinea Pigs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006918" MajorTopicYN="N">Hydroxyurea</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007211" MajorTopicYN="N">Indoles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020024" MajorTopicYN="Y">Leukotriene Antagonists</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007975" MajorTopicYN="N">Leukotriene B4</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017998" MajorTopicYN="N">Leukotriene D4</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016859" MajorTopicYN="Y">Lipoxygenase Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="Y">Membrane Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009240" MajorTopicYN="N">N-Formylmethionine Leucyl-Phenylalanine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D048448" MajorTopicYN="N">Phenylcarbamates</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018077" MajorTopicYN="Y">Receptors, Leukotriene</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018102" MajorTopicYN="N">Receptors, Leukotriene B4</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014105" MajorTopicYN="N">Tosyl Compounds</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014132" MajorTopicYN="N">Trachea</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1997</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1997</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1997</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9105085</ArticleId><ArticleId IdType="doi">10.1164/ajrccm.155.4.9105085</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>